SAT-305 effects of empagliflozin vs placebo on cardiorenal outcomes in people with type 2 diabetes and proteinuric diabetic kidney disease: insights from empa-REG outcome
Abstract
EFFECTS OF EMPAGLIFLOZIN VS PLACEBO ON CARDIORENAL OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND PROTEINURIC DIABETIC KIDNEY DISEASE: INSIGHTS FROM EMPA-REG OUTCOME Wanner MD, C*, Zinman, B, von Eynatten, M, Koitka-Weber, A, Zwiener, I, Hauske, SJ Würzburg University Clinic, Division of NephrologyDepartment of Medicine, Würzburg, Germany, Lunenfeld-Tanenbaum Research InstituteMount Sinai HospitalUniversity of Toronto, Diabetes Centre, Toronto, Canada, Boehringer Ingelheim International GmbH, Medical Affairs, Ingelheim, Germany, Monash University, Department of DiabetesCentral Clinical School, Melbourne, Australia
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.